Skip to contents

  2. Nachtkamp, Kathrin [Author]; Strupp, Corinna [Author]; Vukelja, M. [Author]; Kasprzak, A. [Author]; Haase, D. [Author]; Ganster, C. [Author]; Hildebrandt, B. [Author]; Betz, B. [Author]; Giagounidis, Aristoteles [Author]; Aul, Christina [Author]; Blum, S. [Author]; Hofmann, Wolf-Karsten [Author]; Pfeilstöcker, M. [Author]; Valent, Peter [Author]; Lübbert, M. [Author]; Seidl, M. [Author]; Rudelius, M. [Author]; Stauder, R. [Author]; Krieger, O. [Author]; Götze, K. S. [Author]; Bobak, J. [Author]; Kündgen, A. [Author]; Schulz, F. [Author]; Dietrich, S. [Author]; [...]

    The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms : validation based on the Düsseldorf MDS Registry and proposals for a merged classification : letter

    Articles
    View online
    Schließen
    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    23 January 2024

    Published in: Leukemia ; 38(2024), 2, Seite 442-445

  14. LoRusso, P.; Krop, I. E.; Burris, H. A.; Vukelja, S. J.; Miller, K.; Zheng, M.; Chu, Y.; Lu, M.; Amler, L. C.; Rugo, H. S.

    Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Clinical Oncology (ASCO), 2010

    Published in: Journal of Clinical Oncology

  15. Burris, H.; Vukelja, S.; Krop, I.; Modi, S.; Klencke, B.; Girish, S.; Sliwkowski, M.X.; Dresser, M.; Phillips, G.L.; Rugo, H.

    5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    Elsevier BV, 2009

    Published in: European Journal of Cancer Supplements

  16. LoRusso, P.; Girish, S.; Burris, H.; Beeram, M.; Vukelja, S.; Modi, S.; Yi, J.; Wang, B.; Saad, O.; Gupta, M.

    Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC)

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Association for Cancer Research (AACR), 2009

    Published in: Cancer Research

  17. Vogel, C. L.; Burris, H. A.; Limentani, S.; Borson, R.; O'Shaughnessy, J.; Vukelja, S.; Agresta, S.; Klencke, B.; Birkner, M.; Rugo, H.

    A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Clinical Oncology (ASCO), 2009

    Published in: Journal of Clinical Oncology

  19. Loesch, D. M.; Greco, F.; O’Shaughnessy, J.; Hainsworth, J. D.; Vukelja, S. J.; Sandbach, J.; Boehm, K. A.; Ilegbodu, D.; Asmar, L.; Robert, N. J.

    A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer

    Articles
    View online
    Schließen

    Access

    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Clinical Oncology (ASCO), 2007

    Published in: Journal of Clinical Oncology